## Tim Forshew

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8183320/publications.pdf

Version: 2024-02-01

30	7,409	24 h-index	29
papers	citations		g-index
30	30	30	12462 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	Liquid BlOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)—a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma. British Journal of Cancer, 2022, 126, 1186-1195.	6.4	32
2	Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)., 2021, 9, e001504.		72
3	Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246. Nature Communications, 2018, 9, 771.	12.8	356
4	Comprehensive molecular characterisation of epilepsy-associated glioneuronal tumours. Acta Neuropathologica, 2018, 135, 115-129.	7.7	57
5	Dynamics of multiple resistance mechanisms in plasma DNA during EGFRâ€targeted therapies in nonâ€small cell lung cancer. EMBO Molecular Medicine, 2018, 10, .	6.9	61
6	Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells. Nature Medicine, 2018, 24, 1204-1215.	30.7	133
7	Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling. PLoS ONE, 2018, 13, e0193802.	2.5	90
8	Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA. PLoS ONE, 2018, 13, e0194630.	<b>2.</b> 5	117
9	MAPK pathway activation in the embryonic pituitary results in stem cell compartment expansion, differentiation defects and provides insights into the pathogenesis of papillary craniopharyngioma. Development (Cambridge), 2017, 144, 2141-2152.	2.5	58
10	Digital PCR analysis of circulating tumor DNA: a biomarker for chondrosarcoma diagnosis, prognostication, and residual disease detection. Cancer Medicine, 2017, 6, 2194-2202.	2.8	26
11	Abstract 3639: Analytical performance and validation of an enhanced TAm-Seq circulating tumor DNA sequencing assay. Cancer Research, 2016, 76, 3639-3639.	0.9	14
12	Molecular analysis of pediatric brain tumors identifies microRNAs in pilocytic astrocytomas that target the MAPK and NF-ÎB pathways. Acta Neuropathologica Communications, 2015, 3, 86.	5.2	40
13	Somatic Mutation Screening Using Archival Formalin-Fixed, Paraffin-Embedded Tissues by Fluidigm Multiplex PCR and Illumina Sequencing. Journal of Molecular Diagnostics, 2015, 17, 521-532.	2.8	25
14	Clinical and pathological impact of <i>VHL, PBRM1, BAP1, SETD2, KDM6A</i> , and <i>JARID1c</i> in clear cell renal cell carcinoma. Genes Chromosomes and Cancer, 2014, 53, 38-51.	2.8	107
15	Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nature Genetics, 2014, 46, 837-843.	21.4	302
16	Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer. New England Journal of Medicine, 2013, 368, 1199-1209.	27.0	1,884
17	Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature, 2013, 497, 108-112.	27.8	1,443
18	Mutant p53 Prolongs NF-κB Activation and Promotes Chronic Inflammation and Inflammation-Associated Colorectal Cancer. Cancer Cell, 2013, 23, 634-646.	16.8	388

#	Article	IF	CITATION
19	Comparative Expression Analysis Reveals Lineage Relationships between Human and Murine Gliomas and a Dominance of Glial Signatures during Tumor Propagation <i>In Vitro</i> . Cancer Research, 2013, 73, 5834-5844.	0.9	28
20	Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA. Science Translational Medicine, 2012, 4, 136ra68.	12.4	1,086
21	<i>RAF</i> gene fusion breakpoints in pediatric brain tumors are characterized by significant enrichment of sequence microhomology. Genome Research, 2011, 21, 505-514.	<b>5.</b> 5	61
22	Targeted Therapy for <i>BRAFV600E</i> Malignant Astrocytoma. Clinical Cancer Research, 2011, 17, 7595-7604.	7.0	143
23	MAPK pathway activation and the origins of pediatric lowâ€grade astrocytomas. Journal of Cellular Physiology, 2010, 222, 509-514.	4.1	87
24	RAF gene fusions are specific to pilocytic astrocytoma in a broad paediatric brain tumour cohort. Acta Neuropathologica, 2010, 120, 271-273.	7.7	49
25	MYB upregulation and genetic aberrations in a subset of pediatric low-grade gliomas. Acta Neuropathologica, 2010, 120, 731-743.	7.7	61
26	Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. Journal of Pathology, 2009, 218, 172-181.	4.5	270
27	Reconfiguration of genomic anchors upon transcriptional activation of the human major histocompatibility complex. Genome Research, 2008, 18, 1778-1786.	5.5	26
28	Replication Timing Profile Reflects the Distinct Functional and Genomic Features of the MHC Class II Region. Cell Cycle, 2007, 6, 2393-2398.	2.6	6
29	Locus heterogeneity in autosomal recessive congenital cataracts: linkage to 9q and germline HSF4 mutations. Human Genetics, 2005, 117, 452-459.	3.8	74
30	Mutations in VPS33B, encoding a regulator of SNARE-dependent membrane fusion, cause arthrogryposis–renal dysfunction–cholestasis (ARC) syndrome. Nature Genetics, 2004, 36, 400-404.	21.4	313